A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis

Scott Plevy*, Bruce Salzberg, Gert Van Assche, Miguel Regueiro, Daniel Hommes, William Sandborn, Stephen Hanauer, Stephan Targan, Lloyd Mayer, Uma Mahadevan, Matthew Frankel, James Lowder

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

108 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis'. Together they form a unique fingerprint.

Medicine & Life Sciences